Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Seeing some doubt here and on other sites

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Jan 18, 2022 2:38pm

225 Views

Post# 34329756

Seeing some doubt here and on other sites

Once again you are making this about you and me.....it's not about you and me....or your vicious buddies. It's about CLAS-V.....and Nitric Oxide....... and getting to know the company..... And not falling in love with it. .....You guys always avoid the Fundamentals and argue about folks who bring embarassing questions to the party. ......So once we finish shoveling snow for the day ,...... let's talk Fundamentals with regards to CLAS

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale